Bupivacaine Hcl 0,5 % Spinal Fresenius 1 ml Injection.
PDF Leaflet Revision Date: 25 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Induction of spinal anaesthesia.
Dosage (summary)
10 to 20 mg (2 to 4 ml) for adults; smaller doses for elderly and debilitated patients.
Onset of Action / Duration
Onset: 15 mins, Duration: up to 8 hours
Special Populations
- Elderly
- Debilitated patients
- Patients with cardiac disease
- Hepatic impairment
Pregnancy & Breastfeeding
Use with caution; may cause fetal bradycardia and is distributed in breast milk.
Key Drug Interactions
- Cimetidine may decrease clearance
- Amiodarone may have additive cardiac effects
Contraindications
- Hypersensitivity to bupivacaine
- Active CNS disease
- Spinal stenosis
- Coagulation disorders
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Dizziness
Counselling Points
- Ensure resuscitation equipment is available
- Monitor for signs of toxicity
- Avoid fast bolus injection
Serious warnings
- Risk of systemic toxicity
- Cardiac arrest may occur
- Increased risk in elderly and late pregnancy
Important Disclaimer
The Bupivacaine Hcl 0,5 % Spinal Fresenius 1 ml Injection. professional information leaflet below is the property of Fresenius Kabi Manufacturing Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
